SEMA4A and breast carcinoma: As depicted in Fig. 3a–c, breast cancer patients displayed significantly decreased expression of NRP-1 (p < 0.0001), SNAI1 (p < 0.0001) and SEMA4A (p < 0.0001) in PBMCS compared to healthy controls.